Showing results (51-60 of 88) with videos related to
Sort By:
Pageof 9
Cancer Chemotherapy and Pharmacology|May 18, 2010
Reductive metabolism of the dinitrobenzamide mustard anticancer prodrug PR-104 in miceYongchuan Gu, Christopher P Guise, Kashyap Patel, et al.ACS Medicinal Chemistry Letters|May 20, 2017
2-Aminopyrimidine Derivatives as New Selective Fibroblast Growth Factor Receptor 4 (FGFR4) InhibitorsCheng Mo, Zhang Zhang, Christopher P Guise, et al.Clinical and Translational Radiation Oncology|February 9, 2019
Hypoxia-activated prodrugs and (lack of) clinical progress: The need for hypoxia-based biomarker patient selection in phase III clinical trialsLinda Spiegelberg, Ruud Houben, Raymon Niemans, et al.Biochemical Pharmacology|October 23, 2004
Pharmacological and biological evaluation of a series of substituted 1,4-naphthoquinone bioreductive drugsRoger M Phillips, Mohammed Jaffar, Derek J Maitland, et al.Cancer Gene Therapy|November 27, 2021
Bioreductive prodrug PR-104 improves the tumour distribution and titre of the nitroreductase-armed oncolytic adenovirus ONYX-411NTR leading to therapeutic benefitDean C Singleton, Alexandra M Mowday, Chris P Guise, et al.Journal of Medicinal Chemistry|January 9, 2004
DNA-targeted 1,2,4-benzotriazine 1,4-dioxides: potent analogues of the hypoxia-selective cytotoxin tirapazamineMichael P Hay, Frederik B Pruijn, Swarna A Gamage, et al.Journal of Medicinal Chemistry|February 6, 2026
Structure-Based Design of 4-(1-Methyl-1H-indol-3-yl)pyrimidin-2-amine Derivatives as the First Covalent FGFR3 Selective InhibitorsWenjian Zhu, Xiaojuan Chen, Xiaofei Li, et al.Organic & Biomolecular Chemistry|April 17, 2014
Characterisation of radicals formed by the triazine 1,4-dioxide hypoxia-activated prodrug, SN30000Robert F Anderson, Pooja Yadav, Deepa Patel, et al.Cell Chemical Biology|March 7, 2017
Engineering a Multifunctional Nitroreductase for Improved Activation of Prodrugs and PET Probes for Cancer Gene TherapyJanine N Copp, Alexandra M Mowday, Elsie M Williams, et al.The Biochemical Journal|October 4, 2015
Nitroreductase gene-directed enzyme prodrug therapy: insights and advances toward clinical utilityElsie M Williams, Rory F Little, Alexandra M Mowday, et al.Pageof 9